Dr. Reddy's Laboratories (RDY) signed commercialization and license agreements with Bio-Thera Solutions for biosimilars BAT2206 and BAT2506 in Southeast Asia, Bio-Thera said Thursday.
Under the agreements, Bio-Thera will still oversee the development, manufacturing, and supply of the drugs, while Dr. Reddy's will manage the regulatory approval process and commercialization in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.
Dr. Reddy's will also receive exclusive commercial rights to BAT 2206 in Colombia, according to Bio-Thera.
The company said BAT2206 is a proposed biosimilar to Jansen's Stelara, which has been approved in the EU for the treatment of a number of conditions, including moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis in adults.
BAT2506 is a proposed golimumab biosimilar to Simponi, which has been approved in the US for a number of conditions, including severe rheumatoid arthritis and active psoriatic arthritis, Bio-Thera said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。